Drugs / CLL1-CD33 cCAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03795779 | Mar 2018 → Sep 2022 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | iCell Gene Therapeutics | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLL1-CD33 cCAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03795779 ↗ |
| Known as | CLL1-CD33 cCAR | “CLL1-CD33 cCAR is a compound Chimeric Antigen Receptor (cCAR) immunotherapy with two distinct functional CAR molecules expressed on a T-cell, directed against the surface...” NCT03795779 ↗ |
| Action | Deplete | “Targeting both bulk disease and leukemic stem cells together allows for a more comprehensive ablation of the disease.” NCT03795779 ↗ |
| Modality | Cell therapy | “CLL1-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs.” NCT03795779 ↗ |
| Target | CD33 | “directed against the surface proteins CLL1 and CD33” NCT03795779 ↗ |